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Abstract Alzheimer’s disease is characterized pathologically
by extracellular amyloid L protein (AL) deposition in the brain.
The AL peptide, a 39^42 amino acid fragment, is derived from
de¢ned proteolysis of the amyloid precursor protein (APP)
[Glenner et al., Appl. Pathol. 2 (1984) 357^369; Selkoe, Neuron
6 (1991) 487^498] and is the primary component of senile
plaques. Although it is known that intracellular APP is sub-
jected to posttranslational modi¢cation, the molecular mecha-
nism that regulates the APP processing is not completely clear.
In the present study, we demonstrates that H89, a speci¢c in-
hibitor for cAMP dependent protein kinase A (PKA), inhibits
AL production and APP secretion in a dose dependent manner
in cells stably transfected with human APP bearing a ‘Swedish
mutation’. Concurrent with the e¡ect, H89 inhibits C-terminal
fragment of the APP. We also found that the PKA inhibitor
abolishes the mature form of intracellular APP and accumulates
the immature form. Finally, direct administration of H89 into
brains of transgenic mice overexpressing human APP shows
that the compound inhibits AL production in the hippocampal
region. Our data suggests that PKA plays an important role in
the maturation of APP associated with APP processing.
? 2003 Published by Elsevier Science B.V. on behalf of the
Federation of European Biochemical Societies.
Key words: Amyloid L protein; Protein kinase A;
Amyloid precursor protein; Protein kinase A inhibitor
1. Introduction
The hallmarks of Alzheimer’s disease (AD) neuropathology
are senile plaques and neuro¢brillary tangles. Plaques consist
primarily of L-amyloid (AL), a 39^42 amino acid fragment
derived from de¢ned proteolysis of amyloid precursor protein
(APP) [1^4], while the neuro¢brillary tangles are composed
largely of hyperphosphorylated tau [5,6]. APP is a transmem-
brane glycoprotein and is thought to be cleaved by secretases
(K, L and Q) in the secretory pathway generating AL peptide
and secreted APP. Several lines of evidence have suggested
that posttranslational modi¢cation of APP plays an important
role in intracellular sorting, secretion, axon transport as well
as processing of APP protein. Western blot analysis of APP
from the human cerebrospinal £uid treated with N-glycanase
and O-glycanase showed that APP is both N- and O-glyco-
sylated [7,8]. The immature form of APP (imAPP) is pre-
dominantly N-glycosylated and localized in the endoplasmic
reticulum/cis-Golgi. The mature form (mAPP) is an N,O-gly-
cosylated species concentrated in the trans-Golgi/plasma
membrane [9]. Treatment of transfected hippocampal neurons
with the N-glycosylation inhibitor tunicamycin induces mis-
sorting of wild-type APP, suggesting the importance of glyco-
sylation in axonal sorting of APP [10]. In addition, studies
with site-directed mutagenesis at two potential N-linked gly-
cosylation sites of APP also demonstrated that expression of
the mutant APP led to aberrant APP processing and sug-
gested that the glycosylation may modulate the intracellular
sorting of APP in COS-1 cells [11]. Moreover, studies with
mutated N- and O-glycosylation sites in CHO cells showed
that APP secretion was diminished when core N-glycosylation
or N-glycan processing was blocked [8]. Cells expressing the
defective O-glycosylation of APP noticeably decreased the
generation of the intracellular APP carboxy-terminal fragment
(CTF), a product of K-secretase, and both AL40 and AL42 in
medium, L- and Q-secretase products. Consequently, APP was
accumulated in intracellular reticular compartments such as
the endoplasmic reticulum. These results demonstrated that
the majority of APP cleavage by K-, L-, and Q-secretases oc-
curs after O-glycosylation during APP transport through the
Golgi complex or in compartments subsequent to trans-Golgi
of the APP secretory pathway [12].
The cAMP dependent protein kinase (PKA) plays a key
role in many signal transduction processes, mediating the ma-
jority of the known e¡ects of cAMP in eukaryotic cells. PKA
has been implicated in the AD pathology of abnormal tau
phosphorylation leading to neuro¢brillary tangle formation.
A recent study by Jicha et al. [13] demonstrated that PKA
was tightly associated with the neuro¢brillary pathology, po-
sitioning PKA to participate directly in the pathological hy-
perphosphorylation of tau on Ser214 and Ser409 seen in
brains with AD. PKA phosphorylations on tau precede or
are coincident with the initial appearance of ¢lamentous ag-
gregates of tau. However, the role of PKA on APP biology
such as APP secretion and processing is not clear. In this
report, we attempt to elucidate the molecular mechanism
underlying APP secretion and processing using the selective
PKA inhibitor H89 and demonstrate that PKA activity is
required for APP maturation (glycosylation), secretion as
well as APP processing.
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2. Materials and methods
2.1. Cell lines and treatments
All cell lines were cultured at 37‡C and 5% CO2. Swedish (sw)
APP751 and wild type (wt) APP751 stable HEK293 cells clones were
cultured in Dulbecco’s modi¢ed Eagle’s medium (DMEM-F12 3:1)
(Life Technologies, Gaithersburg, MD, USA) supplemented with 5%
fetal bovine serum, 20 mM HEPES, 50 Wg/ml tobramycin, and 300 Wg/
ml G418. Parental 293 cells were grown in identical medium without
the addition of G418. Each cell line was plated to 50^80% con£uence
1 day prior to analysis. The wtAPP751 and swAPP751 stable HEK293
cells were treated with the PKA inhibitors H89 dihydrochloride and
myristoylated protein kinase A inhibitor (PKI, 14^22 amide) (Calbio-
chem, San Diego, CA, USA) in six well culture dishes at 0^20 WM for
7 h prior to harvesting. At appropriate time, supernatants (medium)
were removed and diluted for AL enzyme-linked immunosorbent as-
say (ELISA) and cells were harvested, using trypsin^EDTA, washed
once in phosphate bu¡ered saline (PBS) and then Dounce homoge-
nized (Kontes Dounce) in lysis bu¡er A (10 mM K2HPO4, 1 mM
EDTA, 5 mM EGTA, 10 mM MgCl2, 50 mM L-glycerophosphate,
1 mM Na3VO4, 1% Triton X-100, 2 mM dithiothreitol, 1 WM micro-
cystin, 1 mM phenylmethylsulfonyl £uoride, 10 Wg/ml leupeptin, 1 Wg/
ml pepstatin, 1 Wg/ml aprotinin, pH 7.2) and incubated on ice for 30
min. The cytosolic protein fraction was clari¢ed by microcentrifuging
at 14 000 rpm for 30 min at 4‡C. Total protein concentration of the
supernatants was determined using the BCA protein assay kit (Pierce,
Rockford, IL, USA).
Con£uent HEK293 cells were fed with methionine-free DMEM for
1 h followed by a medium change with methionine-free DMEM 35S
for 2 h. After incubation, cell medium was collected for AL/swAPP
analysis. Adherent cells were rinsed three times with PBS followed by
cell lysis. AL was then immunoprecipitated from cell medium using
monoclonal antibodies 4G8 and 6E10 (Senetek, Maryland Heights,
MO, USA) against AL, and APP from cell lysis using a rabbit anti-
body (BX6) against APP overnight at 4‡C. The following day, protein
G Sepharose (Amersham Pharmacia, Piscataway, NJ, USA) was
added and immune complexes collected at 4‡C rotating for 1^3 h.
Antigen^antibody^protein G pellets were washed ¢ve times with
STEN (STEN wash bu¡er: 50 mM Tris^HCl, 150 mM NaCl, 2 mM
EDTA, 0.2% NP-40), resolved on a 10% sodium dodecyl sulfate^poly-
acrylamide gel electrophoresis, transferred to nitrocellulose, air dried,
and exposed to ¢lm to assess 35S labeling.
2.2. MTT assays
MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bro-
mide; thiazolyl blue) reagent (Sigma, St. Louis, MO, USA) was
used in a colorimetric assay to determine cell viability and assess
cytotoxicity. Assays were performed by adding 10 mg/ml MTT di-
rectly to culture wells, incubating for 1^4 h and then following re-
moval of medium, adding 1 ml 0.05 N HCl and incubating for 10^20
min at room temperature. After incubation, absorbance was read at
596 nm using a Bio-Rad model 3550 96 well microplate reader. The
quantity of formazan is directly proportional to the number of living
cells in culture.
2.3. AL ELISA
Determination of total AL and AL142 was quanti¢ed by a sand-
wich ELISA described previously [14]. Brie£y, cell supernatants were
diluted in specimen bu¡er (0.6% bovine serum albumin, 8 mM
Na2HPO4W7H2O, 1.5 mM NaH2PO4WH2O, 145 mM NaCl, 0.05% thi-
merosal, 0.05% Triton X-405). Samples were loaded onto Immunlon-4
plates, along with a set of AL142 standards diluted in specimen bu¡er
(0^1000 pg/ml) (Bachem, Torrance, CA, USA), and incubated over-
night at 4‡C. Plates were then washed with PBS/0.05% Tween 20, pH
7.4, followed by a 1 h incubation at room temperature with 3D6
biotinylated reporter antibody speci¢c for AL15 (diluted 1:2000 in
0.25% casein bu¡er). Plates were again washed, followed by a 1 h
room temperature incubation with streptavidin^horseradish peroxi-
dase conjugate (Amersham Life Sciences, Arlington Heights, IL,
USA) diluted 1:1000 in 0.25% casein bu¡er. Following a ¢nal series
of washes, TMB substrate (Pierce) was added for 15 min, after which
time the enzymatic reaction was stopped with 2 N H2SO4. Reaction
products were quanti¢ed by measuring the absorbance di¡erence at
450 nm and 650 nm.
2.4. PKA kinase assays
PKA kinase activity was assessed using the Upstate Biotechnology
(UBI, Lake Placid, NY, USA) PKA Kinase Assay kit. Either 10 Wl of
whole cell lysate or 10 Wl of bovine heart puri¢ed PKA catalytic
subunit (UBI) representing 34.48 ng of enzyme was used in kinase
assays. In assays using puri¢ed enzyme, PKA inhibitors were included
at concentrations speci¢ed above. PKA activity was measured in a
total reaction volume of 60 Wl containing 83.3 WM kemptide substrate
(LRRASLG), 1^2 WM cAMP, 0.3 WM PKC inhibitor peptide, 3.3 WM
compound R24571, and 5^10 WCi [Q-32P]ATP in 1Uassay dilution
bu¡er (UBI). PKA assays were incubated at 30‡C for 10 min. Reac-
tions were stopped by spotting onto p81 phosphocellulose ¢lter paper,
washed three times in 0.75% H3PO4, and rinsed in acetone prior to
scintillation counting. Phosphate incorporation in kemptide substrate
peptide was used as a readout of kinase activity. For whole cell lysate
assays, sample cpm were normalized based on total protein concen-
tration.
2.5. Intracerebral ventricle injection of PKA inhibitor, H89
PDAPP (APP717VF) transgenic mice were allowed to acclimate in a
clear 4U4U4 inch observation cage with free access to food pellets.
Eight week old animals (n=10) were injected i.c.v. according to a
method developed by Laursen and Belknap [15]. Brie£y, unanesthe-
tized animals were gently restrained and injected with H89 103 WM.
Injections were made using a 50 Wl Hamilton syringe ¢tted with a 26
gauge needle including a small piece of PE20 tubing slipped over the
needle allowing a 3.7 mm projection. Holding the needle at a 45‡
angle, the bregma was located by feeling, the needle moved laterally
about 2 mm and then pushed into the ventricle. Five microliter of
inhibitor solution was rapidly injected and the animals were returned
to their cage for a 3 h incubation. Three hours post inhibitor injection,
mice were CO2 anesthetized, decapitated and speci¢c brain regions
were isolated following dissection. Hippocampus and cortex tissue
was immediately homogenized in a guanidine HCl solution and as-
sessed using the AL sandwich ELISA.
3. Results and discussion
H89 and PKI are both well-known selective inhibitors of
cAMP dependent protein kinase. H89 is an isoquinolinesulfo-
namide that acts as a competitive inhibitor against ATP for
binding to the catalytic subunit of PKA [16]. PKI is a heat-
stable protein kinase inhibitor peptide that, like the R sub-
units, mimics the protein substrate providing a pseudophos-
phorylation site and functions as a competitive inhibitor by
binding to the catalytic site of PKA [17,18]. We sought to
determine if inhibition of the PKA signal pathway would
a¡ect APP processing. In this study, we used well-character-
ized HEK293 cells stably transfected with wtAPP751 or
swAPP751 [19], producing elevated AL and secreted APP in
the medium. Our data demonstrate that both PKI and H89
treatment lower total AL and AL142 production in the
swAPP cell medium as determined by AL sandwich ELISA
analysis (Fig. 1A,B). Further, we demonstrated that treatment
of swAPP cells with either inhibitor at the highest concentra-
tion (20 WM) does not cause cytotoxicity to the swAPP cells
based on MTT viability analysis (data not shown), suggesting
that an e¡ect on PKA and not reduced cell viability is the
cause of the observed reduction in AL formation. The fact
that PKI delivers less potency could be due to its poorer
cell permeability. In addition to the dose dependent inhibition
of AL in the HEK293 swAPP751 stable cell line, H89 also
demonstrated a strong inhibition of PKA activity in both
swAPP and wtAPP cell lines following H89 addition to the
culture medium (data not shown). This inhibitory e¡ect was
produced at inhibitor concentrations reported in the literature
to be selective for PKA inhibition. Our data further imply
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that PKA enzyme activity plays an important role in the APP
processing.
To con¢rm whether the H89 inhibitor was indeed having an
e¡ect on APP processing, sAPP and AL were speci¢cally im-
munoprecipitated from harvested swAPP751 cell medium fol-
lowing [35S]methionine labeling (Fig. 2). The AL was speci¢-
cally detected in the supernatant by two di¡erent monoclonal
antibodies (6E10/4G8), both recognizing sAPP, AL and P3. In
addition, a rabbit polyclonal antibody (BX6) was used for
detection of APP and CTF in cell lysate. The amount of AL
in cell supernatant was determined by immunoprecipitation.
Complementing our already described data, a reduced level of
AL formation was associated with a decline in APP to almost
zero as H89 concentration was increased (Fig. 2A,B). Further,
in the cell lysate immunoprecipitations, decreased CTF levels
were observed also in response to increasing concentrations of
H89 (Fig. 2C).
APP is subject to glycosylation and phosphorylation fol-
lowing protein synthesis, and is then thought to be cleaved
in an intracellular secretory pathway after or during these
posttranslational modi¢cations [20^22]. One of the posttrans-
lational modi¢cations of APP is N-, O-glycosylation or both.
Following the modi¢cations, cellular APP exists in two iso-
forms, the immature isoform (imAPP), which is normally as-
sociated with N-glycosylation, and the mature isoform
(mAPP), which is N- and O-glycosylated. We therefore
wanted to determine if the posttranslational modi¢cations of
APP play an important role in H89 mediated inhibition of AL
production. Following treatment of swAPP751 cells with H89
at increasing doses, the secretion of sAPP is signi¢cantly re-
duced (Fig. 3A) and the mature form of APP is notably abol-
ished (Fig. 3B). However, the immature form of APP level
increases, suggesting a possible defect in O-glycosylation but
intact N-glycosylation. Additional studies to speci¢cally dis-
tinguish O- from N-glycosylation inhibition by PKA inhibitor
are under way.
PDAPP (APP717VF) transgenic mice over-expressing FAD
APP717VF mutant show elevated AL levels in the brain in an
age dependent manner and progressively develop some of the
pathological hallmarks of AD including numerous extracellu-
lar thio£avin S-positive AL deposits, neuritic plaques, synaptic
loss, astrocytosis and microgliosis [14,23]. In order to assess in
vivo e¡ects of PKA inhibitors on AL deposition, we directly
administered H89 through the lateral ventricle adjacent to the
bregma of brains of PDAPP (APP717VF) transgenic mice.
Following injection in H89, we were able to show that the
PKA inhibitor resulted in a reduction of AL deposition in the
hippocampus (Fig. 4), a prominent brain region a¡ected by
AD pathology, suggesting an in vivo role for PKA in APP
metabolism.
Fig. 1. H89 (A) or PKI (B) treatment lowers total AL and AL142 production in swAPP cells. H89 (20 WM) or PKI (20 WM) does not cause cy-
totoxicity to the swAPP cells (data not shown).
Fig. 2. H89 inhibits sAPP (A), AL production (B) and CTF forma-
tion (C) in the swAPP751 stable cell line as determined by immuno-
precipitation analysis. The AL could be speci¢cally detected in
supernatant by two di¡erent monoclonal antibodies (6E10/4G8).
Antibody BX6 recognizes the APP and CTF in cell lysate. The lev-
els of the secreted APP (sAPP), AL peptides and CTFs are notably
reduced following H89 treatment.
Fig. 3. A: sAPP was immuno-precipitated from supernatants and
the sAPP levels were inhibited by the treatment of H89. B: The ma-
ture isoform of APP was completely abolished and the immature
APP isoform level was increased by H89. The mature isoform is N-
and O-glycosylated (sAPP), whereas the immature isoform is nor-
mally associated with N-glycosylation. Our data suggest that H89
conceivably blocks the maturation of APP by inhibiting the O-gly-
cosylation during APP processing.
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H89, a speci¢c inhibitor of PKA, potently inhibited AL
production in swAPP751 HEK293 cell and brains of transgenic
mice overexpressing APP717VF and the secretion of APP. In-
hibition of PKA blocks the maturation of APP, possibly via
blocking the O-glycosylation of APP, as evidenced by abro-
gation of the mature form and accumulation of the immature
form of APP by H89. It is conceivable that imAPP, unlike
mAPP, fails to be transported to the proper compartments
(e.g. in the trans-Golgi network) in the secretory pathway
for processing or to be recognized by secretases. Our hypoth-
esis is consistent with the observation that APP processing by
K-, L- and Q-secretases occurs after O-glycosylation [12].
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Fig. 4. H89 inhibits AL production in brains of transgenic mice
overexpressing the APP gene bearing the Indiana mutation
(APP717VF). Following direct injection of H89 into the brains of
APP717VF mice, the AL level of hippocampus was measured by
ELISA analysis and was shown to be inhibited by H89. (Veh,
DMSO vehicle).
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